Search - tctmd.com

Displaying 901 - 920 of 4573

Sort: Relevancy | Date

News Industry News

STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years(1)

October 12, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Conference News TCT 2015

Robotic Systems to Play Greater Role in Cath Lab of the Future

Todd Neale

October 12, 2015

News Conference News TCT 2015

Mortality Increasing in Elderly PCI Patients

October 12, 2015

News Industry News

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

October 12, 2015

News Conference News TCT 2015

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

October 12, 2015

News Industry News

Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

October 12, 2015

News Industry News

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

October 12, 2015

News Conference News TCT 2015

Featured Lecture Calls for Integration of New Technologies to Improve Cath Lab Care

Yael L. Maxwell

October 12, 2015

News Conference News TCT 2015

Endovascular Therapies for Stroke Challenge the Adage ‘Time is Brain’

October 12, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Conference News TCT 2015

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

News Conference News TCT 2015

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

October 12, 2015

News Conference News TCT 2015

Absorb BVS Matches Xience V in Chinese Patients

Todd Neale

October 12, 2015

Presentation TCT 2015

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? NO!

Presenter: Carlo Di Mario, Eberhard Grube, Daniel I. Simon

October 11, 2015

Advertisement

STENTYS Sirolimus-Eluting Stent Confirms Best-in-Class Performance at 3 Years(1)

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

Robotic Systems to Play Greater Role in Cath Lab of the Future

Mortality Increasing in Elderly PCI Patients

Medtronic Drug-Filled Stent Shows Promising Initial Results Following First Implants

Intracoronary Brachytherapy Reduces DES ISR but Restenosis not Eliminated

Follow-up imaging data from APPOSITION IV study to be presented at TCT conference in San Francisco

First-In-Man Study Examines Angiographic And Clinical Outcomes Of Newest Bioresorbable Magnesium Stent

Featured Lecture Calls for Integration of New Technologies to Improve Cath Lab Care

Endovascular Therapies for Stroke Challenge the Adage ‘Time is Brain’

DAPT Study Subanalysis Focuses on EES Subgroup

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

BIOSOLVE-II: Novel Absorbable Scaffold Safe, Effective

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

ABSORB II: Absorb BVS, Xience Yield Similar Outcomes at 2 Years

Absorb BVS Matches Xience V in Chinese Patients

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? NO!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content